The common cytokine receptor γ chain family of cytokines

Cold Spring Harbor Perspectives in Biology

Volumn 10, Issue 9, 2018, Pages

  Lin, Jian Xin ^a   Leonard, Warren J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2 RECEPTOR GAMMA;

ANIMAL; AUTOIMMUNE DISEASE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; T-LYMPHOCYTES;

EID: 85053661017     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a028449     Document Type: Review

References (345)

1. Akashi K, Kondo M, von Freeden-Jeffry U, Murray R, Weiss-man IL. 1997. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 89: 1033–1041.
2. + T cell development. J Exp Med 200: 159–168.
3. H17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13: 711–718.
4. Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ. 1996. cDNA cloning and characterization of the human interleukin 13 receptor α chain. J Biol Chem 271: 29265–29270.
5. Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G, et al. 2016. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med 8: 367ra166.
6. Arima N, Kamio M, Imada K, Hori T, Hattori T, Tsudo M, Okuma M, Uchiyama T. 1992. Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the third component that is essential for functional IL-2 binding and signaling. J Exp Med 176: 1265–1272.
7. Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH. 1995. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 154: 483–490.
8. Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita H, Koreth J, Kim HT, et al. 2017. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood 129: 2186– 2197.
9. Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D, Sugamura K. 2001. Cutting edge: The common γ-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 167: 1–5.
10. Attridge K, Wang CJ, Wardzinski L, Kenefeck R, Chamberlain JL, Manzotti C, Kopf M, Walker LS. 2012. IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 119: 4656–4664.
11. Avery DT, Bryant VL, Ma CS, de Waal Malefyt R, Tangye SG. 2008. IL-21-induced isotype switching to IgG and IgA by human naïve B cells is differentially regulated by IL-4. J Immunol 181: 1767–1779.
12. Ballesteros-Tato A, Leon B, Graf BA, Moquin A, Adams PS, Lund FE, Randall TD. 2012. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36: 847–856.
13. Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, Goldman CK, Brennan J, Roessler E, Waldmann TA. 1994. The interleukin (IL) 2 receptor β chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-acti-vated killer cells. Proc Natl Acad Sci 91: 4940–4944.
14. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682–687.
15. + T regulatory cell development during the neonatal period. J Exp Med 201: 769– 777.
16. + T regulatory cells. J Immunol 178: 4062–4071.
17. + T regulatory cells. J Immunol 181: 225–234.
18. Bazan JF. 1990. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci 87: 6934–6938.
19. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, et al. 2014. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371: 130–139.
20. Begitt A, Droescher M, Meyer T, Schmid CD, Baker M, Antunes F, Knobeloch KP, Owen MR, Naumann R, Decker T, et al. 2014. STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling. Nat Immunol 15: 168–176.
21. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. 2001. The immune dysregulation, polyendocrinop-athy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27: 20–21.
22. + T cells. J Immunol 170: 5018–5026.
23. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Wurfel J, Ohayon J, Waldmann TA, et al. 2004. Humanized anti-CD25 (daclizu-mab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proc Natl Acad Sci 101: 8705–8708.
24. bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci 103: 5941–5946.
25. + T cells are required for NK cell activation in vivo upon Leishmania major infection. J Immunol 185: 2174–2181.
26. Boussiotis VA, Barber DL, Nakarai T, Freeman GJ, Gribben JG, Bernstein GM, D’Andrea AD, Ritz J, Nadler LM. 1994. Prevention of T cell anergy by signaling through the γc chain of the IL-2 receptor. Science 266: 1039–1042.
27. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. 2006. Selective stimulation of T cell subsets with anti-body-cytokine immune complexes. Science 311: 1924–1927.
28. Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. 2003. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102: 4090–4098.
29. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. 2001. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27: 68–73.
30. Bubier JA, Sproule TJ, Foreman O, Spolski R, Shaffer DJ, Morse HC 3rd, Leonard WJ, Roopenian DC. 2009. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci 106: 1518–1523.
31. Buckley RH. 2011. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: Longterm outcomes. Immunol Res 49: 25–43.
32. + regulatory T cells. J Immunol 178: 280–290.
33. Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E, Waldmann TA. 1994. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lympho-kine-activated killer cells. Proc Natl Acad Sci 91: 4935– 4939.
34. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, Russell SM, Drago J, Noguchi M, Grinberg A, Bloom ET, et al. 1995. Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity 2: 223–238.
35. Carbone G, Wilson A, Diehl SA, Bunn J, Cooper SM, Rincon M. 2013. Interleukin-6 receptor blockade selectively re- duces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int J Biol Sci 9: 279– 288.
36. Caruso R, Botti E, Sarra M, Esposito M, Stolfi C, Diluvio L, Giustizieri ML, Pacciani V, Mazzotta A, Campione E, et al. 2009. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15: 1013–1015.
37. Cerwenka A, Lanier LL. 2016. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol 16: 112–123.
38. Chang HY, Nadeau KC. 2017. IL-4Rα inhibitor for atopic disease. Cell 170: 222.
39. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Bris-sette WH, et al. 2003. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875–878.
40. Chen X, Bhandari R, Vinkemeier U, Van Den Akker F, Darnell JE Jr, Kuriyan J. 2003. A reinterpretation of the dimerization interface of the N-terminal domains of STATs. Protein Sci 12: 361–365.
41. Chen F, Liu Z, Wu W, Rozo C, Bowdridge S, Millman A, Van Rooijen N, Urban JF Jr, Wynn TA, Gause WC. 2012. An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection. Nat Med 18: 260–266.
42. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, Wang YH, Lim H, Reynolds JM, Zhou XH, et al. 2011. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 17: 983–988.
43. Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, Agarwal A, Huang W, Parkhurst CN, Muratet M, et al. 2012. A validated regulatory network for Th17 cell specification. Cell 151: 289–303.
44. Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, Suter T, Becher B. 2011. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuro-inflammation. Nat Immunol 12: 560–567.
45. Concannon P, Rich SS, Nepom GT. 2009. Genetics of type 1A diabetes. N Engl J Med 360: 1646–1654.
46. Cordeiro Gomes A, Hara T, Lim VY, Herndler-Brandstetter D, Nevius E, Sugiyama T, Tani-Ichi S, Schlenner S, Richie E, Rodewald HR, et al. 2016. Hematopoietic stem cell niches produce lineage-instructive signals to control mul-tipotent progenitor differentiation. Immunity 45: 1219– 1231.
47. Cosman D, Cerretti DP, Larsen A, Park L, March C, Dower S, Gillis S, Urdal D. 1984. Cloning, sequence and expression of human interleukin-2 receptor. Nature 312: 768–771.
48. Cote-Sierra J, Foucras G, Guo L, Chiodetti L, Young HA, Hu-Li J, Zhu J, Paul WE. 2004. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci 101: 3880– 3885.
49. Crotty S. 2014. T follicular helper cell differentiation, function, and roles in disease. Immunity 41: 529–542.
50. + T cell longevity. Cell 161: 750–761.
51. − effector T cells. Nat Immunol 9: 1347–1355.
52. Darnell JE Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415–1421.
53. + T regulatory cells. J Immunol 178: 4022–4026.
54. Demoulin JB, Uyttenhove C, Van Roost E, DeLestre B, Donckers D, Van Snick J, Renauld JC. 1996. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol Cell Biol 16: 4710–4716.
55. Demoulin JB, Van Roost E, Stevens M, Groner B, Renauld JC. 1999. Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9. J Biol Chem 274: 25855–25861.
56. + T cells to drive STAT3-dependent plasma cell differentiation in B cells. Immunol Cell Biol 90: 802–811.
57. Druez C, Coulie P, Uyttenhove C, Van Snick J. 1990. Functional and biochemical characterization of mouse P40/ IL-9 receptors. J Immunol 145: 2494–2499.
58. Dubois S, Mariner J, Waldmann TA, Tagaya Y. 2002. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17: 537–547.
59. Dugas B, Renauld JC, Pene J, Bonnefoy JY, Peti-Frere C, Braquet P, Bousquet J, Van Snick J, Mencia-Huerta JM. 1993. Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol 23: 1687– 1692.
60. Dukovich M, Wano Y, Le thi Bich T, Katz P, Cullen BR, Kehrl JH, Greene WC. 1987. A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Nature 327: 518–522.
61. Durai V, Murphy KM. 2016. Functions of murine dendritic cells. Immunity 45: 719–736.
62. H 17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12: 568–575.
63. + natural regulatory T cells. Proc Natl Acad Sci 106: 12885–12890.
64. Eming SA, Wynn TA, Martin P. 2017. Inflammation and metabolism in tissue repair and regeneration. Science 356: 1026–1030.
65. Fischer A, Le Deist F, Hacein-Bey-Abina S, Andre-Schmutz I, Basile Gde S, de Villartay JP, Cavazzana-Calvo M. 2005. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev 203: 98–109.
66. + regulatory T cells. Nat Immunol 4: 330–336.
67. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142–1151.
68. Gessner A, Blum H, Rollinghoff M. 1993. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology 189: 419–435.
69. Giliani S, Mori L, de Saint Basile G, Le Deist F, Rodriguez-Perez C, Forino C, Mazzolari E, Dupuis S, Elhasid R, Kessel A, et al. 2005. Interleukin-7 receptor α (IL-7Rα) deficiency: Cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients. Immunol Rev 203: 110–126.
70. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D, Anderson D. 1994. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13: 2822–2830.
71. Gomez-Rodriguez J, Meylan F, Handon R, Hayes ET, Anderson SM, Kirby MR, Siegel RM, Schwartzberg PL. 2016. Itk is required for Th9 differentiation via TCR-mediated induction of IL-2 and IRF4. Nat Commun 7: 10857.
72. Goodwin RG, Lupton S, Schmierer A, Hjerrild KJ, Jerzy R, Clevenger W, Gillis S, Cosman D, Namen AE. 1989. Human interleukin 7: Molecular cloning and growth factor activity on human and murine B-lineage cells. Proc Natl Acad Sci 86: 302–306.
73. Goswami R, Kaplan MH. 2011. A brief history of IL-9. J Immunol 186: 3283–3288.
74. Goswami R, Jabeen R, Yagi R, Pham D, Zhu J, Goenka S, Kaplan MH. 2012. STAT6-dependent regulation of Th9 development. J Immunol 188: 968–975.
75. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Sriniva-san S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al. 1994. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 264: 965–968.
76. Grant CR, Liberal R, Mieli-Vergani G, Vergani D, Longhi MS. 2015. Regulatory T-cells in autoimmune diseases: Challenges, controversies and—yet—unanswered questions. Autoimmun Rev 14: 105–116.
77. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, et al. 2010. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 207: 1871–1878.
78. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, et al. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 18: 1185–1193.
79. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D. 2013. Low-dose interleukin 2 in patients with type 1 diabetes: A phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 1: 295–305.
80. Hatakeyama M, Tsudo M, Minamoto S, Kono T, Doi T, Miyata T, Miyasaka M, Taniguchi T. 1989. Interleukin-2 receptor β chain gene: Generation of three receptor forms by cloned human α and β chain cDNA’s. Science 244: 551–556.
81. + T cells, but not natural killer cells. J Exp Med 184: 289–293.
82. + T cell subsets in patients with systemic lupus erythematosus. Nat Med 22: 991–993.
83. Herber D, Brown TP, Liang S, Young DA, Collins M, Du-nussi-Joannopoulos K. 2007. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 178: 3822–3830.
84. Herold KC, Vignali DA, Cooke A, Bluestone JA. 2013. Type 1 diabetes: Translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 13: 243–256.
85. + T cells for adoptive immunotherapy. Blood 111: 5326–5333.
86. + T cell-dependent activation of NK cells following vaccination. J Immunol 185: 2808–2818.
87. Hou J, Schindler U, Henzel WJ, Ho TC, Brasseur M, McKnight SL. 1994. An interleukin-4-induced transcription factor: IL-4 Stat. Science 265: 1701–1706.
88. Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Ha-maoka T, Paul WE. 1982. Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J Exp Med 155: 914–923.
89. Huang W, Ochs HD, Dupont B, Vyas YM. 2005. The Wiskott–Aldrich syndrome protein regulates nuclear translocation of NFAT2 and NF-κB (RelA) independently of its role in filamentous actin polymerization and actin cyto-skeletal rearrangement. J Immunol 174: 2602–2611.
90. Hultner L, Druez C, Moeller J, Uyttenhove C, Schmitt E, Rude E, Dormer P, Van Snick J. 1990. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 20: 1413– 1416.
91. Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, et al. 2016. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci 113: E7788–E7797.
92. International Multiple Sclerosis Genetics Consortium; Well-come Trust Case Control Consortium; Sawcer S, Hellen-thal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsi-anas L, Dilthey A, Su Z, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214–219.
93. International Multiple Sclerosis Genetics Consortium; Bee-cham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemp-pinen A, Cotsapas C, Shah TS, Spencer C, Booth D, et al. 2013. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45: 1353–1360.
94. Isakson PC, Pure E, Vitetta ES, Krammer PH. 1982. T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J Exp Med 155: 734–748.
95. Jandl C, Liu SM, Canete PF, Warren J, Hughes WE, Vogelzang A, Webster K, Craig ME, Uzel G, Dent A, et al. 2017. IL-21 restricts T follicular regulatory T cell proliferation through Bcl-6 mediated inhibition of responsiveness to IL-2. Nat Commun 8: 14647.
96. Jensen CT, Kharazi S, Boiers C, Cheng M, Lubking A, Sit-nicka E, Jacobsen SE. 2008. FLT3 ligand and not TSLP is the key regulator of IL-7-independent B-1 and B-2 B lymphopoiesis. Blood 112: 2297–2304.
97. Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, Khaled AR, Durum SK. 2005. Cell biology of IL-7, a key lympho-trophin. Cytokine Growth Factor Rev 16: 513–533.
98. Jin H, Carrio R, Yu A, Malek TR. 2004. Distinct activation signals determine whether IL-21 induces B cell costimu-lation, growth arrest, or Bim-dependent apoptosis. J Immunol 173: 657–665.
99. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, Dent AL, Craft J, Crotty S. 2009. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325: 1006–1010.
100. FH cell differentiation. J Exp Med 209: 243–250.
101. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, et al. 2012. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491: 119–124.
102. Jungel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, Michel BA, Gay RE, Emmrich F, Gay S, et al. 2004. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 50: 1468–1476.
103. Junttila IS, Creusot RJ, Moraga I, Bates DL, Wong MT, Alonso MN, Suhoski MM, Lupardus P, Meier-Scheller-sheim M, Engleman EG, et al. 2012. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat Chem Biol 8: 990–998.
104. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4: 1191–1198.
105. + T cells favors terminal-effector differentiation in vivo. Immunity 32: 91–103.
106. Kaplan MH, Hufford MM, Olson MR. 2015. The development and in vivo function of T helper 9 cells. Nat Rev Immunol 15: 295–307.
107. Karrich JJ, Jachimowski LC, Nagasawa M, Kamp A, Balzar-olo M, Wolkers MC, Uittenbogaart CH, Marieke van Ham S, Blom B. 2013. IL-21-stimulated human plasma-cytoid dendritic cells secrete granzyme B, which impairs their capacity to induce T-cell proliferation. Blood 121: 3103–3111.
108. Kashima N, Nishi-Takaoka C, Fujita T, Taki S, Yamada G, Hamuro J, Taniguchi T. 1985. Unique structure of murine interleukin-2 as deduced from cloned cDNAs. Nature 313: 402–404.
109. Kawahara A, Minami Y, Miyazaki T, Ihle JN, Taniguchi T. 1995. Critical role of the interleukin 2 (IL-2) receptor γ-chain-associated Jak3 in the IL-2-induced c-fos and c-myc, but not bcl-2, gene induction. Proc Natl Acad Sci 92: 8724–8728.
110. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, et al. 2000. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191: 771–780.
111. Kermouni A, Van Roost E, Arden KC, Vermeesch JR, Weiss S, Godelaine D, Flint J, Lurquin C, Szikora JP, Higgs DR, et al. 1995. The IL-9 receptor gene (IL9R): Genomic structure, chromosomal localization in the pseudoautosomal region of the long arm of the sex chromosomes, and identification of IL9R pseudogenes at 9qter, 10pter, 16pter, and 18pter. Genomics 29: 371–382.
112. Khaled AR, Li WQ, Huang J, Fry TJ, Khaled AS, Mackall CL, Muegge K, Young HA, Durum SK. 2002. Bax deficiency partially corrects interleukin-7 receptor α deficiency. Immunity 17: 561–573.
113. Kimura Y, Takeshita T, Kondo M, Ishii N, Nakamura M, Van Snick J, Sugamura K. 1995. Sharing of the IL-2 receptor γ chain with the functional IL-9 receptor complex. Int Immunol 7: 115–120.
114. Kiniwa T, Enomoto Y, Terazawa N, Omi A, Miyata N, Ishi-wata K, Miyajima A. 2016. NK cells activated by Interleukin-4 in cooperation with Interleukin-15 exhibit distinctive characteristics. Proc Natl Acad Sci 113: 10139–10144.
115. Kitano M, Moriyama S, Ando Y, Hikida M, Mori Y, Kurosaki T, Okada T. 2011. Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. Immunity 34: 961–972.
116. Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K, Sugamura K. 1993. Sharing of the interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4. Science 262: 1874–1877.
117. Kondo M, Takeshita T, Higuchi M, Nakamura M, Sudo T, Nishikawa S, Sugamura K. 1994. Functional participation of the IL-2 receptor γ chain in IL-7 receptor complexes. Science 263: 1453–1454.
118. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, et al. 2011. Interleukin-2 and regulatory T cells in graft-ver-sus-host disease. N Engl J Med 365: 2055–2066.
119. H 17 cells. Nature 448: 484–487.
120. Kotlarz D, Zietara N, Uzel G, Weidemann T, Braun CJ, Die-stelhorst J, Krawitz PM, Robinson PN, Hecht J, Puchalka J, et al. 2013. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med 210: 433–443.
121. Kritikou JS, Dahlberg CI, Baptista MA, Wagner AK, Baner-jee PP, Gwalani LA, Poli C, Panda SK, Karre K, Kaech SM, et al. 2016. IL-2 in the tumor microenvironment is necessary for Wiskott–Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. Sci Rep 6: 30636.
122. + memory T cells by opposing cytokines. Science 288: 675–678.
123. Kuhn R, Rajewsky K, Muller W. 1991. Generation and analysis of interleukin-4 deficient mice. Science 254: 707–710.
124. Kuperman D, Schofield B, Wills-Karp M, Grusby MJ. 1998. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med 187: 939–948.
125. Kwon H, Thierry-Mieg D, Thierry-Mieg J, Kim HP, Oh J, Tunyaplin C, Carotta S, Donovan CE, Goldman ML, Tailor P, et al. 2009. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 31: 941–952.
126. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD, Garcia KC. 2008. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/ 13 system. Cell 132: 259–272.
127. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, Hennighausen L, et al. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26: 371–381.
128. Lauwerys BR, Garot N, Renauld JC, Houssiau FA. 2000. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol 165: 1847–1853.
129. H17 differentiation by preventing Runx1-medi-ated activation of the gene encoding RORγt. Nat Immunol 12: 96–104.
130. Lee LF, Logronio K, Tu GH, Zhai W, Ni I, Mei L, Dilley J, Yu J, Rajpal A, Brown C, et al. 2012. Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci 109: 12674–12679.
131. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, Skapenko A. 2010. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 62: 2876–2885.
132. Lenardo MJ. 1991. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 353: 858–861.
133. Leonard WJ. 1996. The molecular basis of X-linked severe combined immunodeficiency: Defective cytokine receptor signaling. Annu Rev Med 47: 229–239.
134. Leonard WJ. 2001. Cytokines and immunodeficiency diseases. Nat Rev Immunol 1: 200–208.
135. Leonard WJ, O’Shea JJ. 1998. Jaks and STATs: Biological implications. Annu Rev Immunol 16: 293–322.
136. Leonard WJ, Depper JM, Crabtree GR, Rudikoff S, Pum-phrey J, Robb RJ, Kronke M, Svetlik PB, Peffer NJ, Waldmann TA, et al. 1984. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 311: 626–631.
137. Leonard WJ, Kronke M, Peffer NJ, Depper JM, Greene WC. 1985. Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sci 82: 6281–6285.
138. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, et al. 2012. Exploit-ing a natural conformational switch to engineer an interleukin-2 “superkine.” Nature 484: 529–533.
139. Li MO, Rudensky AY. 2016. T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat Rev Immunol 16: 220–233.
140. Li P, Spolski R, Liao W, Wang L, Murphy TL, Murphy KM, Leonard WJ. 2012. BATF-JUN is critical for IRF4-medi-ated transcription in T cells. Nature 490: 543–546.
141. Li J, Lu E, Yi T, Cyster JG. 2016. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells. Nature 533: 110–114.
142. Liao W, Schones DE, Oh J, Cui Y, Cui K, Roh TY, Zhao K, Leonard WJ. 2008. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor α-chain expression. Nat Immunol 9: 1288– 1296.
143. Liao W, Lin JX, Wang L, Li P, Leonard WJ. 2011. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 12: 551– 559.
144. Liao W, Lin JX, Leonard WJ. 2013. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38: 13–25.
145. Liao W, Spolski R, Li P, Du N, West EE, Ren M, Mitra S, Leonard WJ. 2014. Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc Natl Acad Sci 111: 3508– 3513.
146. Licona-Limon P, Henao-Mejia J, Temann AU, Gagliani N, Licona-Limon I, Ishigame H, Hao L, Herbert DR, Flavell RA. 2013. Th9 cells drive host immunity against gastrointestinal worm infection. Immunity 39: 744–757.
147. Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, Zhou L, Yamauchi A, Bloom ET, Mietz J, John S, et al. 1995. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2: 331–339.
148. Lin JX, Li P, Liu D, Jin HT, He J, Ata Ur Rasheed M, Rochman Y, Wang L, Cui K, Liu C, et al. 2012. Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 36: 586–599.
149. Linehan LA, Warren WD, Thompson PA, Grusby MJ, Ber-ton MT. 1998. STAT6 is required for IL-4-induced germ-line Ig gene transcription and switch recombination. J Immunol 161: 302–310.
150. + follicular regulatory T cells control the germinal center response. Nat Med 17: 975–982.
151. + T cells prevents development of experimental autoimmune diseases. J Immunol 180: 6070–6076.
152. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, Ma A. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9: 669–676.
153. Lorenzen I, Dingley AJ, Jacques Y, Grotzinger J. 2006. The structure of the interleukin-15α receptor and its implications for ligand binding. J Biol Chem 281: 6642–6647.
154. Lu Y, Hong S, Li H, Park J, Hong B, Wang L, Zheng Y, Liu Z, Xu J, He J, et al. 2012. Th9 cells promote antitumor immune responses in vivo. J Clin Invest 122: 4160–4171.
155. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O’Shea JJ, et al. 1995. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377: 65–68.
156. Maki K, Sunaga S, Komagata Y, Kodaira Y, Mabuchi A, Karasuyama H, Yokomuro K, Miyazaki JI, Ikuta K. 1996. Interleukin 7 receptor-deficient mice lack γδ T cells. Proc Natl Acad Sci 93: 7172–7177.
157. Malek TR, Castro I. 2010. Interleukin-2 receptor signaling: At the interface between tolerance and immunity. Immunity 33: 153–165.
158. Malek TR, Porter BO, Codias EK, Scibelli P, Yu A. 2000. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J Immunol 164: 2905–2914.
159. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. 2002. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17: 167–178.
160. Malin S, McManus S, Cobaleda C, Novatchkova M, Delogu A, Bouillet P, Strasser A, Busslinger M. 2010. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol 11: 171–179.
161. Maraskovsky E, Peschon JJ, McKenna H, Teepe M, Strasser A. 1998. Overexpression of Bcl-2 does not rescue impaired B lymphopoiesis in IL-7 receptor-deficient mice but can enhance survival of mature B cells. Int Immunol 10: 1367–1375.
162. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y. 2000. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci 97: 11445–11450.
163. + T cell differentiation is induced following activation in the absence of γ-chain-dependent cytokine signals. J Immunol 176: 2059–2063.
164. Mazzucchelli R, Durum SK. 2007. Interleukin-7 receptor expression: Intelligent design. Nat Rev Immunol 7: 144– 154.
165. FH gene program. Nat Commun 7: 10285.
166. H-17 cell-mediated pathology. Nat Immunol 8: 1390–1397.
167. McGuire HM, Vogelzang A, Hill N, Flodstrom-Tullberg M, Sprent J, King C. 2009. Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus. Proc Natl Acad Sci 106: 19438–19443.
168. Mehta DS, Wurster AL, Whitters MJ, Young DA, Collins M, Grusby MJ. 2003. IL-21 induces the apoptosis of resting and activated primary B cells. J Immunol 170: 4111–4118.
169. Melen E, Gullsten H, Zucchelli M, Lindstedt A, Nyberg F, Wickman M, Pershagen G, Kere J. 2004. Sex specific protective effects of interleukin-9 receptor haplotypes on childhood wheezing and sensitisation. J Med Genet 41: e123.
170. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, et al. 2010. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7: 41.
171. Mitoma H, Horiuchi T, Kimoto Y, Tsukamoto H, Uchino A, Tamimoto Y, Miyagi Y, Harada M. 2005. Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus. Int J Mol Med 16: 609–615.
172. Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, et al. 2015. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 42: 826–838.
173. Mizel SB, Farrar JJ. 1979. Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors. Cell Immunol 48: 433–436.
174. Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J, Bridges G, Palucka AK, Banchereau J. 2001. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 194: 1013–1020.
175. Montandon R, Korniotis S, Layseca-Espinosa E, Gras C, Megret J, Ezine S, Dy M, Zavala F. 2013. Innate pro-B-cell progenitors protect against type 1 diabetes by regulating autoimmune effector T cells. Proc Natl Acad Sci 110: E2199–E2208.
176. −/– mice. J Immunol 157: 2366–2373.
177. Morgan DA, Ruscetti FW, Gallo R. 1976. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007–1008.
178. + T cells. Proc Natl Acad Sci 99: 8832–8837.
179. Nakamura Y, Russell SM, Mess SA, Friedmann M, Erdos M, Francois C, Jacques Y, Adelstein S, Leonard WJ. 1994. Heterodimerization of the IL-2 receptor β-and γ-chain cytoplasmic domains is required for signalling. Nature 369: 330–333.
180. Namen AE, Lupton S, Hjerrild K, Wignall J, Mochizuki DY, Schmierer A, Mosley B, March CJ, Urdal D, Gillis S. 1988. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 333: 571–573.
181. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. 1999. The IL-4 receptor: Signaling mechanisms and biologic functions. Annu Rev Immunol 17: 701–738.
182. Nelson BH, Lord JD, Greenberg PD. 1994. Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation. Nature 369: 333– 336.
183. Nikaido T, Shimizu A, Ishida N, Sabe H, Teshigawara K, Maeda M, Uchiyama T, Yodoi J, Honjo T. 1984. Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature 311: 631–635.
184. Niu X, He D, Zhang X, Yue T, Li N, Zhang JZ, Dong C, Chen G. 2010. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol 71: 334–341.
185. + T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci 94: 10838– 10843.
186. Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X, Leonard WJ. 1993a. Interleukin-2 receptor γ chain: A functional component of the interleukin-7 receptor. Science 262: 1877–1880.
187. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ. 1993b. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73: 147– 157.
188. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, Ihle JN. 1995. Defective lymphoid development in mice lacking Jak3. Science 270: 800–802.
189. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, Coyle AJ, Kasper LH, Noelle RJ. 2009. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 206: 1653–1660.
190. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, et al. 2007. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448: 480–483.
191. Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, Wang YH, Watowich SS, Jetten AM, Tian Q, et al. 2008. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29: 138–149.
192. FH-like gene profile. Nat Immunol 13: 405–411.
193. Ohara J, Paul WE. 1987. Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature 325: 537–540.
194. Ohkura N, Kitagawa Y, Sakaguchi S. 2013. Development and maintenance of regulatory T cells. Immunity 38: 414–423.
195. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. 2003. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426: 671–676.
196. Orange JS, Roy-Ghanta S, Mace EM, Maru S, Rak GD, San-born KB, Fasth A, Saltzman R, Paisley A, Monaco-Shawver L, et al. 2011. IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-in-dependent human NK cell function. J Clin Invest 121: 1535–1548.
197. Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. 2000. Cloning of a type I cytokine receptor most related to the IL-2 receptor β chain. Proc Natl Acad Sci 97: 11439– 11444.
198. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, Morse HC III, Liu C, Schwartzberg PL, Leonard WJ. 2002. A critical role for IL-21 in regulating immunoglobulin production. Science 298: 1630–1634.
199. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF, Hwu P, Shaffer DJ, Akilesh S, Roopenian DC, et al. 2004. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 173: 5361–5371.
200. Pahwa R, Chatila T, Pahwa S, Paradise C, Day NK, Geha R, Schwartz SA, Slade H, Oyaizu N, Good RA. 1989. Recombinant interleukin 2 therapy in severe combined immunodeficiency disease. Proc Natl Acad Sci 86: 5069–5073.
201. Pai SY, Truitt ML, Ho IC. 2004. GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. Proc Natl Acad Sci 101: 1993–1998.
202. Pandey A, Ozaki K, Baumann H, Levin SD, Puel A, Farr AG, Ziegler SF, Leonard WJ, Lodish HF. 2000. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat Immunol 1: 59–64.
203. Pandiyan P, Yang XP, Saravanamuthu SS, Zheng L, Ishihara S, O’Shea JJ, Lenardo MJ. 2012. The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes. J Immunol 189: 4237–4246.
204. Park LS, Martin U, Garka K, Gliniak B, Di Santo JP, Muller W, Largaespada DA, Copeland NG, Jenkins NA, Farr AG, et al. 2000. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: Formation of a functional heteromeric complex requires interleukin 7 receptor. J Exp Med 192: 659–670.
205. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, et al. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57–63.
206. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. 2002. Interleukin-21 and the IL-21 receptor: Novel effectors of NK and T cell responses. J Leukoc Biol 72: 856–863.
207. Paul WE. 2015. History of interleukin-4. Cytokine 75: 3–7.
208. Pene J, Gauchat JF, Lecart S, Drouet E, Guglielmi P, Boulay V, Delwail A, Foster D, Lecron JC, Yssel H. 2004. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol 172: 5154–5157.
209. Perol L, Lindner JM, Caudana P, Nunez NG, Baeyens A, Valle A, Sedlik C, Loirat D, Boyer O, Creange A, et al. 2016. Loss of immune tolerance to IL-2 in type 1 diabetes. Nat Commun 7: 13027.
210. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, et al. 1994. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 180: 1955–1960.
211. Petit-Frere C, Dugas B, Braquet P, Mencia-Huerta JM. 1993. Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. Immunology 79: 146–151.
212. H17 axis determines the onset of autoimmune disease. Nat Immunol 18: 104–113.
213. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. 2010. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32: 79–90.
214. Pot C, Jin H, Awasthi A, Liu SM, Lai CY, Madan R, Sharpe AH, Karp CL, Miaw SC, Ho IC, et al. 2009. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinate-ly act together to promote differentiation of IL-10-pro-ducing Tr1 cells. J Immunol 183: 797–801.
215. + severe combined immunodeficiency. Nat Genet 20: 394–397.
216. Pulendran B. 2015. The varieties of immunological experience: Of pathogens, stress, and dendritic cells. Annu Rev Immunol 33: 563–606.
217. Pulliam SR, Uzhachenko RV, Adunyah SE, Shanker A. 2016. Common γ chain cytokines in combinatorial immune strategies against cancer. Immunol Lett 169: 61–72.
218. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM, Khoury SJ, Fuhlbrigge RC, Kuchroo VK, et al. 2012. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 18: 1248– 1253.
219. Qi H. 2016. T follicular helper cells in space-time. Nat Rev Immunol 16: 612–625.
220. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. 1989. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci 86: 10029– 10033.
221. Quelle FW, Shimoda K, Thierfelder W, Fischer C, Kim A, Ruben SM, Cleveland JL, Pierce JH, Keegan AD, Nelms K, et al. 1995. Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol Cell Biol 15: 3336–3343.
222. + T cells shows that PD-1 inhibits T cell function by upreg-ulating BATF. Nat Med 16: 1147–1151.
223. Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, Donlin LT, Henderson LA, Wei K, Mizoguchi F, et al. 2017. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 542: 110–114.
224. Rasheed MA, Latner DR, Aubert RD, Gourley T, Spolski R, Davis CW, Langley WA, Ha SJ, Ye L, Sarkar S, et al. 2013. Interleukin-21 is a critical cytokine for the generation of virus-specific long-lived plasma cells. J Virol 87: 7737– 7746.
225. Rasmussen TK, Andersen T, Hvid M, Hetland ML, Horslev-Petersen K, Stengaard-Pedersen K, Holm CK, Deleuran B. 2010. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol 37: 2014–2020.
226. Rathmell JC, Farkash EA, Gao W, Thompson CB. 2001. IL-7 enhances the survival and maintains the size of naïve T cells. J Immunol 167: 6869–6876.
227. Ray JP, Staron MM, Shyer JA, Ho PC, Marshall HD, Gray SM, Laidlaw BJ, Araki K, Ahmed R, Kaech SM, et al. 2015. The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells. Immunity 43: 690–702.
228. Recher M, Berglund LJ, Avery DT, Cowan MJ, Gennery AR, Smart J, Peake J, Wong M, Pai SY, Baxi S, et al. 2011. IL-21 is the primary common γ chain-binding cytokine required for human B-cell differentiation in vivo. Blood 118: 6824–6835.
229. Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. 2005. The structure of interleukin-2 complexed with its α receptor. Science 308: 1477–1480.
230. c family cytokines. Nat Rev Immunol 9: 480–490.
231. Rolling C, Treton D, Pellegrini S, Galanaud P, Richard Y. 1996. IL4 and IL13 receptors share the γc chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells. FEBS Lett 393: 53–56.
232. Rosenberg SA. 2014. IL-2: The first effective immunotherapy for human cancer. J Immunol 192: 5451–5458.
233. + T cells. Immunity 45: 685–700.
234. Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, Friedmann MC, Miyajima A, Puri RK, Paul WE, et al. 1993. Interleukin-2 receptor γ chain: A functional component of the interleukin-4 receptor. Science 262: 1880–1883.
235. Russell SM, Johnston JA, Noguchi M, Kawamura M, Bacon CM, Friedmann M, Berg M, McVicar DW, Witthuhn BA, Silvennoinen O, et al. 1994. Interaction of IL-2R β and γc chains with Jak1 and Jak3: Implications for XSCID and XCID. Science 266: 1042–1045.
236. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, et al. 1995. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 270: 797–800.
237. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253–261.
238. Sage PT, Sharpe AH. 2015. T follicular regulatory cells in the regulation of B cell responses. Trends Immunol 36: 410– 418.
239. Sage PT, Sharpe AH. 2016. T follicular regulatory cells. Immunol Rev 271: 246–259.
240. Sage PT, Ron-Harel N, Juneja VR, Sen DR, Maleri S, Sung-nak W, Kuchroo VK, Haining WN, Chevrier N, Haigis M, et al. 2016. Suppression by TFR cells leads to durable and selective inhibition of B cell effector function. Nat Immunol 17: 1436–1446.
241. Saikh KU, Khan AS, Kissner T, Ulrich RG. 2001. IL-15-induced conversion of monocytes to mature dendritic cells. Clin Exp Immunol 126: 447–455.
242. Saito Y, Tada H, Sabe H, Honjo T. 1991. Biochemical evidence for a third chain of the interleukin-2 receptor. J Biol Chem 266: 22186–22191.
243. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151–1164.
244. Salzer E, Kansu A, Sic H, Majek P, Ikinciogullari A, Dogu FE, Prengemann NK, Santos-Valente E, Pickl WF, Bilic I, et al. 2014. Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency. J Allergy Clin Immunol 133: 1651– 1659 e1612.
245. Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezy-chowski W, et al. 2017. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376: 1723–1736.
246. Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J, Wakeland EK, Li QZ, Wandstrat AE, Karp DR, et al. 2008. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 67: 458–461.
247. Schlissel MS, Durum SD, Muegge K. 2000. The interleukin 7 receptor is required for T cell receptor γ locus accessibility to the V(D)J recombinase. J Exp Med 191: 1045–1050.
248. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. 2000. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol 1: 426–432.
249. + T cells but is not a general T cell growth factor. Eur J Immunol 19: 2167–2170.
250. + T cells depends on IL-2, is synergistically enhanced by a combination of TGF-β and IL-4, and is inhibited by IFN-γ. J Immunol 153: 3989–3996.
251. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I. 1991. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352: 621–624.
252. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723–735.
253. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, Giltnane JM, Yang L, Zhao H, Calame K, et al. 2002. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17: 51–62.
254. Sharon M, Klausner RD, Cullen BR, Chizzonite R, Leonard WJ. 1986. Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science 234: 859–863.
255. Sheng W, Yang F, Zhou Y, Yang H, Low PY, Kemeny DM, Tan P, Moh A, Kaplan MH, Zhang Y, et al. 2014. STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflamma-tion. Cell Res 24: 1387–1402.
256. Shi M, Lin TH, Appell KC, Berg LJ. 2008. Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 28: 763–773.
257. Shiraishi M, Shintani Y, Shintani Y, Ishida H, Saba R, Yamaguchi A, Adachi H, Yashiro K, Suzuki K. 2016. Alternatively activated macrophages determine repair of the infarcted adult murine heart. J Clin Invest 126: 2151– 2166.
258. Shirley M. 2017a. Daclizumab: A review in relapsing multiple sclerosis. Drugs 77: 447–458.
259. Shirley M. 2017b. Dupilumab: First global approval. Drugs 77: 1115–1121.
260. Siegel JP, Sharon M, Smith PL, Leonard WJ. 1987. The IL-2 receptor β chain (p70): Role in mediating signals for LAK, NK, and proliferative activities. Science 238: 75–78.
261. Smith GA, Uchida K, Weiss A, Taunton J. 2016. Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling. Nat Chem Biol 12: 373–379.
262. L induction. Cell 98: 181–191.
263. Soldaini E, John S, Moro S, Bollenbacher J, Schindler U, Leonard WJ. 2000. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol 20: 389–401.
264. Spangler JB, Tomala J, Luca VC, Jude KM, Dong S, Ring AM, Votavova P, Pepper M, Kovar M, Garcia KC. 2015. Antibodies to interleukin-2 elicit selective T cell subset poten-tiation through distinct conformational mechanisms. Immunity 42: 815–825.
265. Spolski R, Leonard WJ. 2014. Interleukin-21: A double-edged sword with therapeutic potential. Nat Rev Drug Discov 13: 379–395.
266. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ. 2008. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci 105: 14028–14033.
267. Spolski R, Kim HP, Zhu W, Levy DE, Leonard WJ. 2009. IL-21 mediates suppressive effects via its induction of IL-10. J Immunol 182: 2859–2867.
268. Sprent J, Surh CD. 2011. Normal T cell homeostasis: The conversion of naïve cells into memory-phenotype cells. Nat Immunol 12: 478–484.
269. Stepensky P, Keller B, Abuzaitoun O, Shaag A, Yaacov B, Unger S, Seidl M, Rizzi M, Weintraub M, Elpeleg O, et al. 2015. Extending the clinical and immunological phenotype of human interleukin-21 receptor deficiency. Hae-matologica 100: e72–e76.
270. Su EW, Moore CJ, Suriano S, Johnson CB, Songalia N, Patterson A, Neitzke DJ, Andrijauskaite K, Garrett-Mayer E, Mehrotra S, et al. 2015. IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med 7: 311ra170.
271. Suarez-Fueyo A, Bradley SJ, Klatzmann D, Tsokos GC. 2017. T cells and autoimmune kidney disease. Nat Rev Nephrol 13: 329–343.
272. Surh CD, Sprent J. 2008. Homeostasis of naïve and memory T cells. Immunity 29: 848–862.
273. Suto A, Nakajima H, Hirose K, Suzuki K, Kagami S, Seto Y, Hoshimoto A, Saito Y, Foster DC, Iwamoto I. 2002. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Cɛ transcription of IL-4-stimulated B cells. Blood 100: 4565–4573.
274. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H, et al. 1995. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 268: 1472–1476.
275. Takeshita T, Asao H, Suzuki J, Sugamura K. 1990. An associated molecule, p64, with high-affinity interleukin 2 receptor. Int Immunol 2: 477–480.
276. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, Munakata H, Nakamura M, Sugamura K. 1992. Cloning of the γ chain of the human IL-2 receptor. Science 257: 379–382.
277. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgou-roudis E, Piccirillo CA, Salomon BL, Bluestone JA. 2008. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687–697.
278. Tangye SG. 2015. Advances in IL-21 biology—Enhancing our understanding of human disease. Curr Opin Immunol 34: 107–115.
279. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, Hamuro J. 1983. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302: 305–310.
280. Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, Moy E, Balbo P, Li W, Zhao Y, et al. 2016. Discovery of a JAK3-selective inhibitor: Functional differentiation of JAK3-se-lective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol 11: 3442–3451.
281. Terashima A, Okamoto K, Nakashima T, Akira S, Ikuta K, Takayanagi H. 2016. Sepsis-induced osteoblast ablation causes immunodeficiency. Immunity 44: 1434–1443.
282. Teshigawara K, Wang HM, Kato K, Smith KA. 1987. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med 165: 223–238.
283. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, et al. 2007. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39: 857–864.
284. Townsend JM, Fallon GP, Matthews JD, Smith P, Jolin EH, McKenzie NA. 2000. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 13: 573–583.
285. Tran E, Robbins PF, Rosenberg SA. 2017. “Final common pathway” of human cancer immunotherapy: Targeting random somatic mutations. Nat Immunol 18: 255–262.
286. Tsudo M, Kozak RW, Goldman CK, Waldmann TA. 1986. Demonstration of a non-Tac peptide that binds interleukin 2: A potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci 83: 9694–9698.
287. Turner JE, Morrison PJ, Wilhelm C, Wilson M, Ahlfors H, Renauld JC, Panzer U, Helmby H, Stockinger B. 2013. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med 210: 2951–2965.
288. Ulrich BJ, Verdan FF, McKenzie AN, Kaplan MH, Olson MR. 2017. STAT3 activation impairs the stability of Th9 cells. J Immunol 198: 2302–2309.
289. Uyttenhove C, Simpson RJ, Van Snick J. 1988. Functional and structural characterization of P40, a mouse glycopro-tein with T-cell growth factor activity. Proc Natl Acad Sci 85: 6934–6938.
290. Vahedi G, Takahashi H, Nakayamada S, Sun HW, Sartorelli V, Kanno Y, O’Shea JJ. 2012. STATs shape the active enhancer landscape of T cell populations. Cell 151: 981–993.
291. Van Dyken SJ, Locksley RM. 2013. Interleukin-4-and inter-leukin-13-mediated alternatively activated macrophages: Roles in homeostasis and disease. Annu Rev Immunol 31: 317–343.
292. + regulatory T cell development. J Immunol 181: 3285–3290.
293. H9 cells. Nat Immunol 15: 758–766.
294. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, West-endorf A, Buer J, Martin B, Wilhelm C, Stockinger B. 2008. Transforming growth factor-β “reprograms” the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 9: 1341–1346.
295. Venkatasubramanian S, Cheekatla S, Paidipally P, Tripathi D, Welch E, Tvinnereim AR, Nurieva R, Vankayalapati R. 2017. IL-21-dependent expansion of memory-like NK cells enhances protective immune responses against Mycobacterium tuberculosis. Mucosal Immunol 10: 1031– 1042.
296. Vermeesch JR, Petit P, Kermouni A, Renauld JC, Van Den Berghe H, Marynen P. 1997. The IL-9 receptor gene, located in the Xq/Yq pseudoautosomal region, has an autosomal origin, escapes X inactivation and is expressed from the Y. Hum Mol Genet 6: 1–8.
297. Villarino AV, Stumhofer JS, Saris CJ, Kastelein RA, de Sau-vage FJ, Hunter CA. 2006. IL-27 limits IL-2 production during Th1 differentiation. J Immunol 176: 237–247.
298. Vinkemeier U, Cohen SL, Moarefi I, Chait BT, Kuriyan J, Darnell JE Jr. 1996. DNA binding of in vitro activated Stat1 α, Stat1 β and truncated Stat1: Interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J 15: 5616–5626.
299. Vinkemeier U, Moarefi I, Darnell JE Jr, Kuriyan J. 1998. Structure of the amino-terminal protein interaction domain of STAT-4. Science 279: 1048–1052.
300. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331: 44–49.
301. von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Bur-dach SE, Murray R. 1995. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 181: 1519–1526.
302. Vosshenrich CA, Ranson T, Samson SI, Corcuff E, Colucci F, Rosmaraki EE, Di Santo JP. 2005. Roles for common cytokine receptor γ-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol 174: 1213–1221.
303. Vosshenrich CA, Garcia-Ojeda ME, Samson-Villeger SI, Pasqualetto V, Enault L, Richard-Le Goff O, Corcuff E, Guy-Grand D, Rocha B, Cumano A, et al. 2006. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 7: 1217–1224.
304. Waldmann TA. 2006. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595–601.
305. Waldmann TA. 2015. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplas-tic lymphocytes: Implications for cancer therapy. Cancer Immunol Res 3: 219–227.
306. + human memory T cells. J Exp Med 208: 1875–1887.
307. Wan CK, Oh J, Li P, West EE, Wong EA, Andraski AB, Spolski R, Yu ZX, He J, Kelsall BL, et al. 2013. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 38: 514–527.
308. + T cells. Proc Natl Acad Sci 112: 9394– 9399.
309. Wang LM, Keegan AD, Li W, Lienhard GE, Pacini S, Gut-kind JS, Myers MG Jr, Sun XJ, White MF, Aaronson SA, et al. 1993. Common elements in interleukin 4 and insulin signaling pathways in factor-dependent hematopoietic cells. Proc Natl Acad Sci 90: 4032–4036.
310. Wang X, Lupardus P, Laporte SL, Garcia KC. 2009. Structural biology of shared cytokine receptors. Annu Rev Immunol 27: 29–60.
311. Wang L, Yu CR, Kim HP, Liao W, Telford WG, Egwuagu CE, Leonard WJ. 2011. Key role for IL-21 in experimental autoimmune uveitis. Proc Natl Acad Sci 108: 9542–9547.
312. Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Lan-gefeld CD, Ziegler J, Kimberly RP, Edberg JC, Ramsey-Goldman R, et al. 2009. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 60: 2402–2407.
313. Weinberg K, Parkman R. 1990. Severe combined immunodeficiency due to a specific defect in the production of interleukin-2. N Engl J Med 322: 1718–1723.
314. FH cells progressively differentiate to regulate the germinal center response. Nat Immunol 17: 1197–1205.
315. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobie-randa F, Wang L, Kirkesseli S, Rocklin R, Bock B, et al. 2013. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368: 2455–2466.
316. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, et al. 2016. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388: 31–44.
317. West EE, Jin HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, Tan WG, Youngblood B, Freeman GJ, Smith KA, Ah-med R. 2013. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest 123: 2604–2615.
318. Wilhelm C, Hirota K, Stieglitz B, Van Snick J, Tolaini M, Lahl K, Sparwasser T, Helmby H, Stockinger B. 2011. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 12: 1071–1077.
319. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. 1995. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3: 521–530.
320. Winthrop KL. 2017. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13: 234–243.
321. Wirth JJ, Kierszenbaum F, Zlotnik A. 1989. Effects of IL-4 on macrophage functions: Increased uptake and killing of a protozoan parasite (Trypanosoma cruzi). Immunology 66: 296–301.
322. Wu Z, Kim HP, Xue HH, Liu H, Zhao K, Leonard WJ. 2005. Interleukin-21 receptor gene induction in human T cells is mediated by T-cell receptor-induced Sp1 activity. Mol Cell Biol 25: 9741–9752.
323. Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, Matsuura E, Maric D, Waldmann TA, Bielekova B. 2011. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 17: 604–609.
324. Wynn TA, Vannella KM. 2016. Macrophages in tissue repair, regeneration, and fibrosis. Immunity 44: 450–462.
325. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O’Neill G, Neyer L, Sheridan J, Wang C, et al. 2010. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon β. Lancet Neurol 9: 381–390.
326. Wynn TA, Chawla A, Pollard JW. 2013. Macrophage biology in development, homeostasis and disease. Nature 496: 445–455.
327. Xu X, Sun YL, Hoey T. 1996. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science 273: 794–797.
328. Xu M, Liu M, Du X, Li S, Li H, Li X, Li Y, Wang Y, Qin Z, Fu YX, et al. 2015. Intratumoral delivery of IL-21 overcomes anti-Her2/Neu resistance through shifting tumor-associ-ated macrophages from M2 to M1 phenotype. J Immunol 194: 4997–5006.
329. Xue HH, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN, Leonard WJ. 2002. IL-2 negatively regulates IL-7 receptor α chain expression in activated T lymphocytes. Proc Natl Acad Sci 99: 13759–13764.
330. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Ca-nales J, Zhu J, Grainger JR, Hirahara K, Sun HW, Wei L, Vahedi G, et al. 2011. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12: 247–254.
331. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, Li D, Durum SK, Jiang Q, Bhandoola A, et al. 2006. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci 103: 1000–1005.
332. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT, Laurence A, Robinson GW, Shevach EM, Moriggl R, et al. 2007. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109: 4368–4375.
333. Ye SK, Agata Y, Lee HC, Kurooka H, Kitamura T, Shimizu A, Honjo T, Ikuta K. 2001. The IL-7 receptor controls the accessibility of the TCRγ locus by Stat5 and histone acetylation. Immunity 15: 813–823.
334. Yin T, Keller SR, Quelle FW, Witthuhn BA, Tsang ML, Lienhard GE, Ihle JN, Yang YC. 1995. Interleukin-9 induces tyrosine phosphorylation of insulin receptor sub-strate-1 via JAK tyrosine kinases. J Biol Chem 270: 20497– 20502.
335. Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Hori-kawa M, Kountikov EI, Spolski R, Poe JC, Leonard WJ, Tedder TF. 2012. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 491: 264–268.
336. Yu D, Rao S, Tsai LM, Lee SK, He Y, Sutcliffe EL, Srivastava M, Linterman M, Zheng L, Simpson N, et al. 2009. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 31: 457–468.
337. Yu CR, Oh HM, Golestaneh N, Amadi-Obi A, Lee YS, Eseonu A, Mahdi RM, Egwuagu CE. 2011. Persistence of IL-2 expressing Th17 cells in healthy humans and experimental autoimmune uveitis. Eur J Immunol 41: 3495–3505.
338. Yu A, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A, Malek TR. 2015. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 64: 2172–2183.
339. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188: 2205–2213.
340. + T cell expansion and function. J Exp Med 201: 139–148.
341. Zeng R, Spolski R, Casas E, Zhu W, Levy DE, Leonard WJ. 2007. The molecular basis of IL-21-mediated proliferation. Blood 109: 4135–4142.
342. + regulatory T cells and for expansion of these cells. J Immunol 178: 2018–2027.
343. H-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8: 967–974.
344. Zhu J, Cote-Sierra J, Guo L, Paul WE. 2003. Stat5 activation plays a critical role in Th2 differentiation. Immunity 19: 739–748.
345. H2 responses. Nat Immunol 5: 1157–1165.